Deals of the year 2009: High grade –Swiss pharma Roche provides cure for quality concerns

Swiss pharma's €12.66 billion bond perfect medicine in ultra-cautious market.

Global Awards
High grade High-yield
Equity M&A
Structured credit Restructuring
Regional Awards
Asia Latin America
CEE Middle East
Roche Eurobond and sterling issue: total €12.66 billion equivalent
4-year 6-year 7-year 12-year
€5.25 bln £1.25 bln €2.75 bln €1.75 bln
Issuer: Roche
Amount: €12.66 billion
Arrangers: Barclays Capital, BNP Paribas, Deutsche Bank, Santander
 

Take yourself back to the beginning of 2009. A dark cloud hung over the financial markets, the banking system had just been bailed out, yet systemic risk still lingered. The effects of massive central bank stimulus and government-backed bank bond guarantees had yet to kick fully into the sector.

Access intelligence that drives action

To unlock this research, enter your email to log in or enquire about access